Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 202 of the 217 references it cites were found in a registry or an index; 71 of the 117 sources its claims cite were checked for support.

Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies

Open access
Buccellato, Francesca R., D’Anca, Marianna, Tartaglia, Gianluca Martino, Del Fabbro, Massimo, Scarpini, Elio, Galimberti, Daniela · 2023 · International Journal of Molecular Sciences

Abstract

In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of dementia and one of the first chronic diseases in elderly people. With 55 million people affected, the WHO considers AD to be a disease with public priority. Unfortunately, there are no final cures for this pathology. Treatment strategies are aimed to mitigate symptoms, i.e., acetylcholinesterase inhibitors (AChEI) and the N-Methyl-D-aspartate (NMDA) antagonist Memantine. At present, the best approaches for managing the disease seem to combine pharmacological and non-pharmacological therapies to stimulate cognitive reserve. Over the last twenty years, a number of drugs have been discovered acting on the well-established biological hallmarks of AD, deposition of β-amyloid aggregates and accumulation of hyperphosphorylated tau protein in cells. Although previous efforts disappointed expectations, a new era in treating AD has been working its way recently. The Food and Drug Administration (FDA) gave conditional approval of the first disease-modifying therapy (DMT) for the treatment of AD, aducanumab, a monoclonal antibody (mAb) designed against Aβ plaques and oligomers in 2021, and in January 2023, the FDA granted accelerated approval for a second monoclonal antibody, Lecanemab. This review describes ongoing clinical trials with DMTs and non-pharmacological therapies. We will also present a future scenario based on new biomarkers that can detect AD in preclinical or prodromal stages, identify people at risk of developing AD, and allow an early and curative treatment.

Overview

CoChat Summary

## TL;DR

This is a narrative review of Alzheimer’s disease (AD) treatment beyond symptomatic therapy, focusing on disease-modifying treatments, stem cells, and non-pharmacological interventions. It argues that earlier diagnosis with biomarkers and earlier treatment are key, and it highlights recent antibody approvals such as aducanumab and lecanemab.

## Key findings

  • The review states that the estimated number of people with AD dementia is about 50 million worldwide, and that this may rise to 150 million by 2050.
  • It says the current symptomatic drugs are acetylcholinesterase inhibitors and memantine, which provide temporary relief but do not cure AD.
  • In phase III clinical trials, the authors report 36 agents in the AD pipeline, of which 25% are DMT-biologics, 42% are DMT small molecules, and 7 agents (19% of the total DMTs) are monoclonal antibodies targeting different parts of Aβ.
  • The review reports multiple trial outcomes: donanemab slowed cognitive decline by 40% on the iADRS in TRAILBLAZER-ALZ 2; lecanemab produced moderately less decline at 18 months in early AD; gantenerumab failed to meet primary endpoints; and solanezumab failed in completed phase 3 trials.

## Methods

  • Narrative literature review of AD treatments “beyond symptomatic therapies,” covering immunotherapy, disease-modifying treatments, stem cells, and non-pharmacological interventions.
  • The authors draw on published studies and clinical trial listings from ClinicalTrials.gov; no original patient sample or new dataset is reported.
  • Main analysis is descriptive synthesis of trial and preclinical evidence, with discussion of trial design issues, biomarker use, and developmental status of therapies.

## Limitations

  • The paper itself does not state formal study limitations; it is a review rather than an empirical study.
  • Evident limitation: the conclusions depend on heterogeneous evidence from preclinical studies, phase II/III trials, and trial registries, rather than a systematic meta-analysis or newly collected data.
  • Evident limitation: several treatment sections are incomplete or only mention ongoing trials, so for some agents the paper cannot provide outcome data yet.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms241813900

Cites

202 of 202 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Summary of Alzheimer’s disease (AD) treatment strategies in clinical trials. Created with Biorender.com.
Figure 1 Summary of Alzheimer’s disease (AD) treatment strategies in clinical trials. Created with Biorender.com.CC BY · PubMed Central

Verification

Claims the paper makes

46 Valid · 4 Not valid · 20 Not checked · 6 Own results and interpretations

33 more claims · 22 with their cited sources checked

Create a free account to see all 76 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 38
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 217 references

Cited by

See all 94

Metadata

Authors
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D.
Affiliations
  • University of Milan (IT)
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
  • Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy
Corresponding author
  • Buccellato, Francesca R.
  • D’Anca, Marianna
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-09-09
Volume
24
Issue
18
Pages
13900
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4386602162
Cited by
94
References
217
Citations by year
2026: 26 · 2025: 35 · 2024: 31 · 2023: 2
FWCI
3.34
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Funders
Italian Ministry of Health
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, disease-modifying therapy, aducanumab, lecanemab, acetylcholinesterase inhibitors, memantine, amyloid plaques, tau hyperphosphorylation, cognitive reserve, non-pharmacological treatment, biomarkers, prodromal Alzheimer's disease, clinical trials
MeSH terms
Acetylcholinesterase, Aged, Alzheimer Disease, Antibodies, Monoclonal, Humans, Memantine, United States, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. https://app.cochat.ai/papers/10.3390/ijms241813900
The paper
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023). Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813900

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.